A phase 3, long-term, open-label safety study of Galcanezumab in patients with migraine

Galcanezumab, a humanized monoclonal antibody that selectively binds to the calcitonin gene-related peptide, has demonstrated in previous Phase 2 and Phase 3 clinical studies ( ≤6-month of treatment) a reductio...

Source: BMC Neurology - November 9, 2018 Category: Neurology Authors: Angelo Camporeale, David Kudrow, Ryan Sides, Shufang Wang, Annelies Van Dycke, Katherine J. Selzler and Virginia L. Stauffer Tags: Research article Source Type: research